The Consortium Ecosystem for Diagnosis Intelligence

---

The "Diagnostic Odyssey" cannot be solved in a silo. It requires a radical convergence of frontline clinical care, deep-tech infrastructure, and patient-led advocacy. Regal Intel serves as the neutral, non-profit fiduciary connecting these critical pillars through our secure diagnostics framework.

We are proud to collaborate with, integrate, and draw guidance from some of the world's leading academic medical centers, patient advocacy networks, and technology innovators to generate actionable diagnosis intelligence.

To map the natural history of rare, complex, and high-velocity diseases, we partner with top-tier academic institutions to transform decades of clinical expertise into regulatory-grade evidence.

• University of Pittsburgh: Advancing rare disease research and transforming retrospective deep-phenotypic data into regulatory-grade natural history models via our diagnostics framework.

• PCORNet: Aligning with national clinical research networks and physiological data repositories to ensure our evidence generation and diagnosis intelligence meet the highest standards of interoperability and patient-centered outcomes.

• PhysioNet: Integrating with the premier global repository of complex physiological signals. We leverage these expansive clinical datasets to benchmark our biological velocity algorithms and mathematically validate our continuous-time disease models within our diagnostics framework.

The patient is our North Star. We work directly with foundation leaders to ensure that their community registries are protected, structured, and ready for therapeutic development.

• Cure GM1 Foundation: Strategic collaboration to build prospective, BIMO-ready Natural History models for GM1 Gangliosidosis.

• National Organization for Rare Disorders (NORD): Active engagement to solve real world data challenges and empower patient communities and standardize decentralized phenotypic data mapping.

• Orphanet: Aligning with the definitive global reference portal for rare diseases and orphan drugs. By mapping our diagnosis intelligence to standardized ORPHA nomenclature, we ensure our synthetic evidence is universally recognized by international regulators and the global research community.

To ensure "Zero Exfiltration" and execute our "Code-to-Data" diagnostic framework, we encourage our consortium partners to build upon the most secure, advanced computational platforms in the world.

• NVIDIA: Utilizing world-class GPU infrastructure and edge-computing frameworks to power our decentralized diagnosis intelligence models securely.

• Google Cloud (BAA Compliant): Leveraging HIPAA-compliant, business-associate-secured infrastructure for the encrypted orchestration of our consortium networks.

IRDiRC (International Rare Diseases Research Consortium): Regal Intel is a contributing member of the IRDiRC Task Force on Digital Twins. Working alongside global regulatory and scientific experts, funders and patient advocates, we are supporting the responsible translation of digital twins into robust evidence by developing recommendations for regulators, developers and policy makers.

Our consortium is guided by a multidisciplinary board of industry veterans, bridging the gap between clinical genetics, patient advocacy, and global pharmaceutical commercialization.

• Sanjay Ahuja, Ph.D.
  Chief Science Officer

• Jerry Vockley, MD, Ph.D.
  Professor of Human Genetics, University of Pittsburgh; Chief of Genetic and Genomic Medicine, UPMC and Director of Center for Rare Disease Therapy, UPMC.

• Dave DeBord
  Chief Operating Officer, Royal Chemical.

• Carl H. Kennedy
  Faculty, Medical University of South Carolina; President Elect, South Carolina American College of Healthcare Executives; Chief Revenue & Strategy Officer, QuantifAI

• James Metzger
  VP & GM, ThermoFisher Scientific

• Vishal Prasad
  President & Founder, Mareana

• Suresh Raman
  VP of Digital, Johnson & Johnson

• Christine Waggoner
  President & Founder, Cure GM1 Foundation